Clinical Evidence


Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy.
HDx therapy enabled by the Theranova Dialyzer
Uremia Retention Molecules and Clinical Outcomes
HDx therapy enabled by the Theranova Dialyzer
Use of regional citrate anticoagulation with medium cut-off membrane: pilot report
HDx therapy enabled by the Theranova Dialyzer
Water saving comparison at different dialysate flows in expanded hemodialysis
HDx therapy enabled by the Theranova Dialyzer
WCN24-1658 Effectiveness of Medium Cut-Off Dialyzers in Hemodialysis Patients: An Economic Analysis.
HDx therapy enabled by the Theranova Dialyzer
What is the role of expanded hemodialysis in renal replacement therapy in 2020?

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.